

Table 1: Contractile responses to S6c and ET-1 in MCA incubated with four different PKC inhibitors

	n	S6c Emax (%)	pEC ₅₀	ET-1 Emax (%)	pEC ₅₀
Control	10	131 ± 7	9.13 ± 0.10	152 ± 6	8.74 ± 0.12
Bisindolylmaleimide I	14	73 ± 8**	8.97 ± 0.08	143 ± 6	8.70 ± 0.08
Chelerythrine chloride	9	102 ± 7	8.95 ± 0.20	139 ± 6	8.77 ± 0.18
PKC inhibitor 20-28	14	67 ± 10**	8.80 ± 0.16	145 ± 7	8.64 ± 0.17
Ro-32-0432	9	6 ± 3***	8.92 ± 0.07***	194 ± 12	8.36 ± 0.09


*P < 0.05, **P < 0.01, ***P < 0.001 compared to control. *n* represents the number of artery segments.

PKC subtype expression

Western blot experiments were carried out using antibodies directed specifically against phosphorylated, and thereby activated, PKC isoforms (α , β I, γ , δ and ϵ). These tests showed that PKCi 20-28 was able to decrease the protein amount of all five PKC subtypes tested, although the decrease was most prominent for PKC δ (38% ± 20% of control, Fig. 4A) and PKC γ (51% ± 36% of control, Fig. 4B). Conversely Ro-32-0432 and Bis I did not decrease the protein levels of the PKC subtypes.

Discussion

This study shows that each of the three general PKC inhibitors attenuates the organ culture induced upregulation of the ET_B receptor mediated contraction seen in rat MCA. A fourth PKC inhibitor, chelerythrine chloride, had no effect on the contractile responses of the arteries, and consequently was not included in the additional experiments. A possible explanation to this lack of effect could be that chelerythrine chloride has been shown to alter vasoconstrictive responses through interaction with various phos-

**Figure 1**

Contractile response towards S6c. Contractile responses towards the ET_B receptor agonist S6c in MCAs incubated for 24 hours (control) and MCAs incubated for 24 hours with PKC inhibitors (Bis I, Ro-32-0432, PKCi 20-28). Each point represents mean value ± S.E.M. For statistical analysis, see Table 1.